Literature DB >> 18705634

Performance of coronary procedures through the transulnar access without assessment of the integrity of the deep palmar arch.

Pedro Beraldo De Andrade1, Marden Tebet, Monica Andrade, Luiz Mattos, Andre Labrunie.   

Abstract

Occurrence of ischemic complications after transulnar coronary procedures is virtually absent. The presence of a complete deep palmar arch in approximately 95% of the population as well as the great capacity of the collateral circulation of the hand might justify these findings. We report the occurrence of complications in 62 patients submitted to coronary procedures through the transulnar approach, without assessment of the integrity of the deep palmar arch by the inverse Allen's test. The rate of asymptomatic occlusion of the ulnar artery was 3%, without any ischemic complication. We believe the performance of Allen's test is not necessary when using transulnar access.

Entities:  

Mesh:

Year:  2008        PMID: 18705634     DOI: 10.1111/j.1540-8183.2008.00388.x

Source DB:  PubMed          Journal:  J Interv Cardiol        ISSN: 0896-4327            Impact factor:   2.279


  4 in total

1.  Percutaneous trans-ulnar artery approach for coronary angiography and angioplasty; A case series study.

Authors:  Farshad Roghani-Dehkordi; Mahmood Hadizadeh; Fatemeh Hadizadeh
Journal:  ARYA Atheroscler       Date:  2015-09

2.  Transulnar versus Transradial Access as a Default Strategy for Percutaneous Coronary Intervention.

Authors:  Bhanwar L Ranwa; Kumari Priti
Journal:  Heart Views       Date:  2019-11-14

3.  Transulnar sheathless percutaneous coronary intervention during bivalirudin infusion in high-risk elderly female with non-ST segment elevation myocardial infarction.

Authors:  Francesco Summaria; Valerio Lucci; Marina Mustilli
Journal:  Heart Int       Date:  2012-06-14

Review 4.  Forearm approach for percutaneous coronary procedures.

Authors:  Zoran Stajic; Radoslav Romanovic; Dragan Tavciovski
Journal:  Acta Inform Med       Date:  2013-12-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.